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In developing mechanistic PK–PD models, incidence of toxic
responses in a population has to be described in relation to
measures of biologically effective dose (BED). We have developed
a simple dose-incidence model that links incidence with BED for
compounds that cause toxicity by depleting critical cellular target
molecules. The BED in this model was the proportion of target
molecule adducted by the dose of toxic compound. Our modeling
approach first estimated the proportion depleted for each dose
and then calculated the tolerance distribution for toxicity in
relation to either administered dose or log of administered dose.
We first examined cases where the mean of the tolerance
distribution for toxicity occurred when a significant proportion
of target had been adducted (i.e., more than half). When a normal
distribution was assumed to exist for the relationship of incidence
and BED, the tolerance distribution based on administered dose
for these cases becomes asymmetrical and logarithmic trans-
formations of the administered dose axis lead to a more symmet-
rical distribution. These linked PK–PD models for tissue
reactivity, consistent with conclusions from other work for re-
ceptor binding models (Lutz et al., 2005), indicate that log normal
distributions with administered dose may arise from normal
distributions for BED and nonlinear kinetics between BED and
administered dose. These conclusions are important for develop-
ing biologically based dose response (BBDR) models that link in-
cidences of toxicity or other biological responses to measures of BED.
Key Words: dose-incidence relationship; logarithm; individual
susceptibility; biologically effective dose; pharmacodynamic
modeling; pharmacokinetic modeling.
Toxic responses in an exposed population arise from a series
of steps that involve level of exposure, absorption of chemical
into the body, delivery of chemical to sensitive tissues,
interactions of these chemicals or their metabolites with
biological targets in tissues, and progression of these cellular
interactions, eventually leading to an increase in the proportion
of individuals with an adverse response. Over the past 25 years,
there have been steady advances in pharmacokinetic (PK)
models that predict tissue concentrations of toxic chemicals
and metabolites for many families of chemicals and simulate
the interactions of these chemicals with tissue constituents (see
Reddy et al., 2005). The subsequent steps, from these
interactions to the expression of toxicity, have not received
the same attention in relation to quantitative modeling.
Pharmacological and toxicological responses can be divided
into two broad classes: reactivity and recognition. Reactivity
refers to the alteration in chemical structures by covalent
interactions with protein or DNA and to alterations in the
cellular environment leading to processes such as protein
denaturation. Recognition is the noncovalent interaction with
specific receptors leading to occupancy of the receptor, which
is followed by signal transduction events. The amounts bound
covalently to tissues or noncovalently bound to specific
receptors represent one possible measure of biologically
effective dose (BED) of chemical at the target tissue. However,
the expected relationship between toxicity and BED also
depends on the mode of action for the toxic response. For
carcinogenicity based on mutation, the amount of DNA
adducts may be the appropriate metric for the BED, i.e., the
risk of cancer may be related to the concentration of specific
pro-mutagenic adducts in critical target genes (Lutz, 1979). For
many other modes of action, toxicity is expected to ensue
because of the alteration of important cellular functions by the
loss of critical macromolecules or by the response to receptor-
mediated processes. In these cases, the BED for specific
responses is expected to be related to the extent of loss of the
critical targets, i.e., to the proportion of cellular macromolec-
ular target adducted or to receptor occupancy. The dose metrics
for these BED take values between 0.0 (no critical site
adducted or receptor bound) and 1.0 (all critical sites adducted
or receptors bound).
Mechanistic pharmacodynamic (PD) models for toxic re-
sponses from chemical exposures have to link these continuous
measures for the BED, i.e., the fraction depleted or fraction
receptor occupancy, with the incidence of toxicity in a pop-
ulation. In these types of models, incidence is described by the
distributions of susceptibility for response in the given
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population (Klaassen, 2001). In at least one example, de-
veloping a linked PK–PD model for chloroform toxicity,
a quantal PD process, cell death, was linked to a measure of
tissue dose, i.e., the rate of chloroform metabolism, using
a normal distribution for repair capacity of cells (Reitz et al.,
1990). In order to develop such linked PK–PD models for
quantal responses at the cellular or organism level, it will be
increasingly necessary to consider what relationship should be
used to relate incidence with measures of BED. The traditional
assumption of log normal2 relationships of incidence to
administered dose (Klaassen, 2001) needs to be revisited to
include a broader consideration of both pharmacokinetic and
pharmacodynamic factors that influence both tissue dose and
BED.
In the accompanying FORUM article (Lutz et al., 2005),
general principles of linking incidence to BED have been
outlined and illustrated schematically for a receptor occupancy
model. In this paper, we apply biochemical and PK principles
to develop a linked dose-incidence model based on a normal
distribution for toxicity in relation to a BED that is based on
loss of some fraction of critical cellular targets. This line of
research is a natural extension of consideration of target tissue
dose or BED as the primary determinants of dose-incidence
curves (Gehring et al., 1976; Andersen et al., 1987). The results
of our modeling indicate that log normal distributions for
incidence and administered dose are likely to arise from the
combination of normal distributions for incidence and BED
coupled with nonlinearities in relationship of BED and
administered dose.
METHODS AND PROCEDURES
Model structures. PK–PD models for incidence in relation to administered
dose include the changing dose level, the relationship of internal tissue dose to
administered dose, the relationship of the BED to the internal dose metric, and
the linkage of incidence to measures of BED. Administered dose, target tissue
dose, and BED are all continuous functions in any individual in the population.
In contrast, toxic responses in a population are described on a quantal scale, i.e.,
as proportions of populations showing a defined endpoint. Each individual, i.e.,
a cell in an organ, or an animal or human in a study population, either does or
does not manifest the effect within a given period of observation. The dose-
incidence relationship for biological effects in the population therefore reflects
the tolerance distribution for toxicity in the investigated population. In our PK–
PD models, these tolerance distributions for toxicity were assumed to be
normally distributed with respect to BED, defined by a mean value (mu) and
a standard deviation (sigma). In words, mu is that level of BED that results in
half the individuals in the population showing the defined effect. Illustrating
this relationship with the model for depletion of critical cell constituents, this
means that 50% of the cells would be killed if the BED reaches the value mu.
Tissue reactivity. In the reactivity-based PK–PD incidence model, the
measure of BED is the proportion of an essential cellular constituent (a target
molecule, TM, such as glutathione or an important macromolecule) that is lost
after treatment. This BED is a continuous variable ranging from 0.0 (no TM lost
to reaction) to 1.0 (all TM lost by reaction during exposure). Here, we estimate
the proportion of an essential cell constituent lost after a single dose of the toxic
compound.
A cellular target molecule (TM) reacts with the toxic compound C with
a second-order rate constant, kso. The rate equation for loss of TM, where C and
TM stand for the concentrations of the respective reaction components is:
dTM=dt¼kso3C3TM ð1Þ
Integrating this equation for various doses gives,
Z
dðTMÞ=TM¼kso3
Z
C dt ð2Þ
And,
ln ðTMt=TM0Þ¼kso3AUC ð3Þ
Substituting dose/clearance for AUC and rearranging for proportion of TM lost
by reaction gives,
ln ðTM0=TMÞ¼ ðkso=clearanceÞ3dose ð4Þ
ðTM0 TMdoseÞ=TM0 ¼ 1expfðkso=clearanceÞ3doseg ð5Þ
BED ðProportion TM LostÞ¼ 1expfk#3doseg ð6Þ
The ratio (kso/clearance) was set to 1.0 for our representative calculations. In
addition, the dose can be back calculated based on the observed proportion of
TM remaining by the simple formula:
dose¼ logðTM0=TMdoseÞ ð7Þ
With this model for reactivity, the BED (adducted fraction TM) is a nonlinear
function of dose, asymptotically approaching 1.0 as dose increases, and follows
an exponential relationship. For the reactivity based PK–PD model (Appendix
A), curves were generated using proportion macromolecule depleted as the
independent variable. For each value of the proportion depleted, dose
calculated from Equation 7, and incidence was calculated using a normal
tolerance distribution for the proportion of target molecule that was depleted.
The resulting incidence curves could then be plotted with various x-axis
variables, i.e., BED, administered dose, or logarithm of administered dose (see
Figs. 1 and 3). Other PBPK models, such as one for steady-state extraction of
vapors from the nose (Andersen et al., 1999), have also been implemented with
dose, rather than time, as the independent variable.
Fitting log normal and normal distributions. Using approaches described
in the accompanying FORUM paper (Lutz et al., 2005), distributions simulated
from this PK–PD model that was linked to normal susceptibility distribution
defined by mean mu and standard deviation sigma were fit to either truncated
versions of cumulative log normal or a cumulative normal distribution,
following U((ln(dose) – m)/s) or U((dose – m)/s), where U is the cumulative
standard normal distribution function. Fitting for m and s was limited to the
central 95% incidence range (0.025 < y < 0.975) that was divided up into one
thousand equidistant dose segments. The sum of the thousand differences
between the incidence curve and the best fit were summed up. The result
corresponds to an area, which was used as a measure of goodness of fit. Smaller
areas represent better fits.
RESULTS
Converting Distributions Based on BED to Distributions
Based on Administered Dose
The dose-incidence model for reactivity was run for various
values of mean mu and standard deviation sigma for proportion
target molecule adducted. The results are shown in Figure 1.
2 Definition: If a variable is normally distributed when represented on
a logarithmical scale, the distribution is called ‘‘log normal’’.
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For a high level of TM depletion required for toxicity (top row;
mu ¼ 0.63), the resulting tolerance distribution is displayed for
incidence versus BED (entered as a normal distribution), versus
dose, or versus log dose. Even though the assumed distribution
with respect to BED was normal (Panel A), the incidence
distribution based on administered dose was skewed (Panel B).
When the calculated incidence was plotted against log dose, the
distribution became more symmetrical (Panel C). For conditions
where a much smaller proportion of depletion is associated with
toxicity (mean mu ¼ 0.25 and sigma ¼ 0.5; bottom row of Fig.
1), the calculated normal distribution is more symmetric than the
log normal distribution (Panel C). The differential behaviors for
low and high values of mu arise due to the asymptotic nature of
the relationship between BED and dose. In regions of low
depletion, the relationship between proportion depletion (the
BED) and dose is nearly linear. Here there is good mapping of
the BED distribution on that for administered dose. In regions
where the mean depletion for toxicity is large, the exponential
relationship of BED to dose leads to increased skewing of the
curve, as shown in Panel B of the top row.
Graphical representation of the fits to normal or log normal
distributions as mu changes is shown in Figure 2. Fits to a log
normal distribution were better than to a normal distribution for
mu-values higher than 0.4, with an optimum at mu ¼ 0.63
(center panel) Below mu ¼ 0.4 the normal distribution was
better, as seen in Figure 1, bottom, for mu ¼ 0.2.
Numeric information on the fits is given in Table 1 for a wide
range of mu-values (0.2 to 0.8) and for two different values of
the standard deviation (sigma ¼ 0.05 or 0.1). The values relate
to relative areas between the dose-incidence curve (the full lines
in Fig. 2) and the respective best-fitting curves (dashed for best-
fitting log normal distribution, dotted for best-fitting normal
distribution). The smaller the area, the better is the fit. Log
normal distributions provided better fit for all mu  0.4. The fit
by a normal distribution deteriorated with increasing mu, while
the fit by a log normal distribution showed an optimum, which
was at a higher value for this function (mu ¼ 0.63). For all
calculations, k# was chosen equal 1. Using other values affected
only the scaling of the dose axis but did not change the shape of
the curves or the results of the comparative fitting.
FIG. 1. Fractional dose-incidence relationships calculated for the PK–PD reactivity model. Frequency distributions are presented for two different
independent variables. Panel A is the incidence curve based on the BED (i.e., the proportion depleted for reactivity); panels B and C show the distribution plotted
versus administered dose, with arithmetic and logarithmic dose scaling, respectively. Top row of panels: mu ¼ 0.63 and sigma ¼ 0.10 for proportion depleted (the
mean value that provides a distribution most closely resembling the log normal). Bottom row of panels: mu ¼ 0.25 and sigma ¼ 0.05.
PK–PD MODELS BASED ON BIOLOGICALLY EFFECTIVE DOSE 333
An increase in the standard deviation sigma from 0.05 to 0.1,
i.e., an increase in the span of individual susceptibilities,
resulted in a decreased fit for both the log normal and the
normal curve. The worsening of fit was more pronounced for
the normal fit. This observation indicates that, the wider the
tolerance distribution, the more can be gained (in terms of
fitting a cumulative normal curve to the data) by representing
the dose-incidence data on a logarithmic dose scale.
Figure 3 shows similar behavior for the receptor-mediated
model analyzed previously (Lutz et al., 2005). Based on
Michaelis–Menten kinetics for the dose–BED relationship,
the log normal representation provided the best fit for mu¼ 0.5.
The difference in the relationship of BED to administered dose
for the two models is readily captured in plots of the hyperbolic
(receptor occupancy) and exponential (reactivity) relationships
shown in Figure 4. With unit values for the Michaelis constant
in the occupancy model or for the constant multiplying dose in
the reactivity model, the exponential curve of the reactivity
model approaches the asymptote more quickly as dose
increases. In either model, the best fit of the resulting
distribution to a log normal occurred with unit values for the
Michaelis constant or the constant in the exponential term in
these normalized representations.
DISCUSSION
Log Normal Distributions
Log normal distributions have fairly consistently provided
better descriptions of dose response curves for incidence of
toxicity in populations of animals than have normal distribu-
tions. On the surface, the success of any consistent relationship
of toxicity with administered dose is not at all expected based
on modern concepts in toxicology. Administered dose is, at
FIG. 2. Fitting a cumulative normal curve (dotted line) and a cumulative
log normal curve (dashed line) to the dose-incidence curves generated by the
PK–PD model for reactivity with BED as proportion of critical target molecules
depleted (our exponential model). The three panels show fits for different
means of the tolerance distribution (mu ¼ 0.2, 0.63 [best fit], and 0.8,
respectively). Standard deviation sigma ¼ 0.05. ‘‘Incidence’’ is the proportion
of individuals expected to be susceptible at a given ‘‘dose’’.
TABLE 1
Fit of Log Normal or Normal Distributions to the Results
of a PK–PD Dose-Incidence Model for Depletion of Critical
Cellular Target Molecule by Chemically Reactive Toxicants
sigma ¼ 0.05 sigma ¼ 0.10
log normal normal log normal normal
mu
0.20 16.37 4.79 29.97 9.24
0.25 12.47 5.11 23.58 10.16
0.30 9.75 5.47 18.66 10.98
0.35 7.69 5.90 14.76 11.85
0.40 6.02 6.39 11.52 12.86
0.45 4.60 6.97 8.68 14.05
0.50 3.30 7.68 6.05 15.49
0.55 2.05 8.54 3.45 17.26
0.60 0.76 9.61 1.84 19.49
0.65 0.72 11.00 2.77 22.40
0.70 2.39 12.86 6.44 26.35
0.75 4.64 15.49 11.89 32.21
0.80 7.94 19.49 19.96 41.86
Note. Table values are the areas between the curves derived for the best-
fitting cumulative log normal and the best-fitting normal dose-response curve
from the exponential dose-incidence relationships for the reactivity PK–PD
model linked to cumulative normal tolerance distributions for cell death
(defined by mean mu and standard deviation sigma). The fitting was limited to
the central 95% incidence range. Fits are better for the smaller values in the
Table. The entry in bold highlight the values of mu where the calculated
distribution in most similar to a log-normal distribution.
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best, an indirect measure of the more important variable, i.e.,
the relevant BED at target tissues. The relationship between
BED and administered dose for any chemical depends
primarily on PK and PD characteristics of specific compounds
and the mode of action by which compounds exert their
biological effects. Thus, this overall relationship is expected to
vary considerably among different compounds. In the face of
this variability, the log normal distribution has been un-
accountably successful in describing incidence of toxic re-
sponses (see Gaddum, 1945).
Koch discussed the mechanisms that could generate loga-
rithmic distributions in various biological contexts (Koch,
1966). One was the case where a toxicant caused an effect
when a minimal concentration was maintained for a certain
period of time. If either the elimination constant or the
minimum required time period above the minimum concen-
tration (but not both) were normally distributed in the
population, a log normal distribution would be expected. This
earlier exercise had motivations similar to the PK–PD model-
ing simulations developed in the present paper. Our work has
shown that a log normal distribution might develop even
though the underlying response of the tissue to toxicant was not
itself defined by a log normal distribution. In the case of Koch’s
example, the toxicity was assumed to occur under equivalent
conditions in all individuals: variability in kinetic parameters
give rise to differences in susceptibility among individuals.
Creating Quantal Dose—Response Relationships from
Continuous Measures
Our examples with reactivity (this paper) and receptor
occupancy (Lutz et al., 2005) convert continuous measures of
BED to quantal (binary) measures of incidence. We are not
aware of other studies that have examined dose-incidence
relationships through PK–PD modeling by linking BEDs with
incidence through tolerance distributions. An earlier PD
modeling study simulated chloroform toxicity by relating rates
of metabolism and probability of cell death. Reitz between
et al. (1990) developed the computational model for chloro-
form cytotoxicity that included a linkage between cell killing
and the rate of metabolism of chloroform. The link was
provided by using a distribution for the maximum rate of
repair in a population of cells. This earlier work has some
similarities to our examination of distributions for toxic
responses. The sensitivity of individual cells was described as
normally distributed with a mean and standard deviation of
a maximum repair rate. For any rate of chloroform metabolism
some portion of cells, i.e., those with repair rates lower than the
rate of metabolism to reactive metabolites, were at risk for cell
death, This distribution of normal distribution of the repair rate
combined with the dose dependent rate of metabolism provided
the relationship of BED with cell killing by chloroform. No
efforts were made with this chloroform model to estimate
whether a dose-incidence curve for this mode of action would
FIG. 3. Fractional dose-incidence relationships calculated for the PK–PD model based on receptor binding, using mean receptor occupancy of mu ¼ 0.5 and
sigma¼ 0.1. Panel A is the incidence curve based on the BED (i.e., the fraction receptor occupancy); panels B and C show the frequency distribution plotted versus
administered dose, with arithmetic and logarithmic dose scaling, respectively.
FIG. 4. Nonlinear relationships between BED and administered dose for
reactivity and receptor occupancy modes of action. In each type model
examined, the dose-BED curve starts at 0.0, and asymptotically approaches 1.0
as dose increases.
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lead to a log normal relationship between incidence and
administered dose.
In two papers (Bogen, 1990; Bogen and Gold, 1997)
carcinogenic responses of several halogenated hydrocarbons
were linked to measures of the metabolized dose. Cancer dose-
incidence curves versus these measures of metabolized dose
were simply assumed to be represented by a log normal
relationship with values for mu and sigma. These distributional
parameters were fit to cancer incidence data and then the fitted
distributions were used to predict cancer incidence for various
exposure scenarios. The approach with these halogenated
compounds was not intended, as with our work, as an attempt
to examine the nature of the expected relationship between
incidence and tissue dose. In addition, the fitting with these
compounds was based on a measure of tissue dose, without
consideration of any relationship between the tissue dose and
a BED.
Models for Tissue Reactivity as a Mode of Action
Here, we assumed a normal susceptibility distribution
between BED and incidence and found that the nonlinearity
for the relationship between administered dose and BED alone
can be sufficient to generate a log normal curve for the
relationship between administered dose and incidence. The
ability of this procedure to recapitulate log normal distributions
for reactivity and for receptor occupancy modes of action
indicates a broader applicability of our results. However, the
PK models used to date for examining this question are highly
simplified. In the future, other examples could be examined by
computer simulation of more complex PK processes rather than
using situations that give rise to simple algebraic relationships
to represent the relationship of BED and dose. Simulation
models, based on more complete PBPK models, could be
developed to explore different modes of toxicity, more varied
dosing regimens, and might even include variability of model
parameters. However, these simulation models would still
explore the same question: do log normal relationships for
administered dose arise from normal relationships for in-
cidence with BED, confounded by nonlinear relationships
between administered dose and BED?
PD Models—Proportionate Responses versus
Tolerance Distributions
A PBPK model was used to assist in conduct of a cancer risk
assessment for vinyl chloride. The BED in this model was the
liver exposure to a reactive intermediate, estimated as daily
amount of vinyl chloride metabolized to an oxirane interme-
diate per unit volume of liver (Clewell et al., 2001). In this
approach to cancer risk assessment, the probability of tumor
was related directly to this BED. A similar type of PK–PD
model-based risk assessment is illustrated by recent work with
formaldehyde (Conolly et al., 2003). Two measures of BED
with this compound considered to be proportional to mutation
rate, i.e., DNA–protein cross-links and cell proliferation, were
measured directly. The probability of tumors at any inhaled
concentration was estimated using a two-stage cancer model in
which cell birth, cell death, and mutation were treated as
stochastic processes. The predicted outcome from the model
represents probability of response at a specified concentration
in a uniform population. These PK–PD modeling approaches
do not invoke a distribution of sensitivities for a diverse group
of individuals (or cells) in a population. They do, however, base
the probability of responses on measures of BEDs.
In these two examples, the response endpoint was cancer,
although the formaldehyde incidence was heavily influenced
by cytotoxicity, cell death, and regenerative cell proliferation.
Our modeling was developed to consider a wider array of cel-
lular processes, including cytotoxicity and receptor-mediated
replication where a good portion of the reserves of the cell have
to be overcome to initiate toxicity or where a high degree of
occupancy has to be achieved to initiate processes leading to
cell division. With the use of the tolerance distribution, the
underlying tissue response more resembles a threshold for any
individual; there is no response up to a certain dose, then
a response above a critical dose. Is this depiction a realistic
picture of cellular response to toxicity or proliferation? In-
creasingly, the responses of cells to stressors appear to be
binary in nature, i.e., all-or-none rather than a graded response.
This pattern is obviously true for responses such as cell death or
cell division; however, all-or-none responses at a cellular level
also appear valid for induction of networks of genes and of
single genes (Louis and Becksei, 2002). These cellular
switches (all-or-none behaviors) are frequently governed by
genetic networks involving autocatalytic mitogen activated
protein kinases (MAPKs) or other nonlinear positive feedback
processes within cells (Bhalla et al., 2002; Ferrell, 2002). The
advent of high throughput genomics and computational
approaches that will allow reconstructing and modeling cell
signaling networks and network perturbations by toxic com-
pounds should permit mechanistic evaluations of response
thresholds and a better mechanistic understanding of tolerance
distributions for toxic responses (Andersen et al., 2005).
Summary
In developing PD models for incidence of toxic responses
associated with loss (or alteration) of biological functions due
to tissue reactivity or receptor occupancy, tolerance distribu-
tions for incidence of responses in a population should be
assumed to be normally distributed in relation to appropriate
measures of BED. This conclusion, based on the modeling
approaches in this paper, is consistent with chemical and
biological considerations about modes of action for toxic
responses by chemical exposures and still approximates log
normal distributions in relation to administered dose for most
situations.
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APPENDIX A
The normal distribution for reactivity has a BED related to proportion of the
macromolecule depleted (MMd) with a mean depletion (mu) and a standard
deviation (sigma). Using Equation 7, with normalization to the composite
parameter value of 1.0, allows calculation of dose and incidence for any
presumed level of depletion from 0.0 to 1.0. The PK–PD models were written in
ACSL (Aegis Technologies, Austin, TX) using the proportion macromolecule
depleted as the independent variable. The reactivity model from Equations 1–7
was then condensed into very simple code with the two equations below. MMinit
would be the initial value to the proportion of unreacted target, i.e., 1.00.
var iable MMd¼ 0:01 ðranges from 0:00 to 1:00Þ
dose¼ logfMMinit=ðMMinitMMdÞg
¼ log=f1=ð1:0MMdÞg
Incidence¼f1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2p*sigma ðMMdÞ
p
g
*expfðMMdmuÞ2=2*sigma2g
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